Hemab Therapeutics Holdings, Inc. (COAG)

Hemab Therapeutics Presents Clinical and Preclinical Data from Sutacimig in Glanzmann Thrombasthenia and Factor VII Deficiency at the ISTH 2026 Congress

Hemab Advances Bleeding Disorder Pipeline

Hemab Therapeutics Presents New Clinical Data from HMB-002 in Von Willebrand Disease and Introduces HMB-003 for Heavy Menstrual Bleeding at the ISTH 2026 Congress

Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the ISTH 2026 Congress

Hemab Therapeutics Details Post-IPO Pipeline Push, Sutacimig Phase III Plans

Hemab Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

Hemab Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

U.S. IPO Weekly Recap: Biotech, Early-Stage Mining, And Bill Ackman Close Out The April IPO Market

Hemab Therapeutics Announces Pricing of Upsized Initial Public Offering